CV CapsoVision, Inc
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1378325 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.4%
TTM net income YoY-29.6%
TTM EPS YoY87.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin49.7%
Operating margin-212.1%
Net margin-210.1%
FCF margin-210.3%
EBITDA margin-210.4%
Returns
ROE-125.0%
ROA-100.1%
ROIC (approx.)-99.6%
Asset turnover0.48x
Leverage & solvency
Liabilities / assets19.5%
Debt / equity0.00x
Current ratio5.07x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.00x
Accruals ratio-0.2%
Payout ratio—
Capex / revenue0.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $13.55M | $11.76M |
| Cost of revenue | $6.38M | $5.38M |
| Gross profit | $7.17M | $6.38M |
| R&D expense | $18.31M | $15.12M |
| SG&A expense | $6.85M | $4.21M |
| Operating income | -$25.52M | -$19.92M |
| Pretax income | -$25.29M | -$19.89M |
| Income tax | $24,000 | $11,000 |
| Net income | -$25.32M | -$19.90M |
| EBITDA | -$25.30M | -$19.71M |
| EPS (basic) | -1.03 | -9.85 |
| EPS (diluted) | -1.03 | -9.85 |
| Weighted avg. shares (diluted) | 24.56M | 2.02M |
| Balance sheet | ||
| Receivables | $2.50M | $2.00M |
| Inventory | $2.99M | $2.63M |
| Current assets | $16.67M | $14.85M |
| PP&E, net | $611,000 | $720,000 |
| Total assets | $18.16M | $16.80M |
| Current liabilities | $4.43M | $1.80M |
| Total liabilities | $4.90M | $2.69M |
| Shareholders' equity | $13.26M | -$129.51M |
| Shares outstanding | 46.87M | 2.09M |
| Cash flow statement | ||
| Operating cash flow | -$22.86M | -$20.09M |
| Capital expenditure | $90,000 | $153,000 |
| Free cash flow | -$22.95M | -$20.24M |
| Investing cash flow | -$90,000 | -$153,000 |
| Financing cash flow | $23.60M | $15.07M |
| Depreciation & amortization | $216,000 | $206,000 |
| Stock-based compensation | $826,000 | $156,000 |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.